PRQR
ProQR Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.50 / 10
Outperform
Analyst consensus is 100% Strong Buy from a single analyst, yet price fell 22% and expectations are neutral. Fund‑flow score is 7.52 (good), with block, large and extra‑large investors net inflowing, while small and medium investors net outflow. Positive liquidity but weak price support.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-04
InstitutionChardan Capital
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for PRQR?
- PRQR holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.50/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
